原发性肿瘤中的DNA倍体和S期分数能否预测转移性乳腺癌对化疗的反应？
Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?
作者信息
Hietanen P, Blomqvist C, Wasenius V M, Niskanen E, Franssila K, Nordling S
机构信息
Department of Radiotherapy and Oncology, University Central Hospital of Helsinki, Finland.
出版信息
Br J Cancer. 1995 May;71(5):1029-32. doi: 10.1038/bjc.1995.198.
Abstract
The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients. The response to chemotherapy was significantly better in patients with tumours with a high SPF, and in addition the time to progression was longer in the high-SPF group. There was no significant difference when the DNA ploidy and response to treatment were compared.
摘要
利用81例患者石蜡包埋的肿瘤组织，研究了环磷酰胺、表柔比星和氟尿嘧啶化疗反应与转移性乳腺癌进展时间以及原发肿瘤的DNA倍体和S期分数（SPF）之间的关系。SPF高的肿瘤患者对化疗的反应明显更好，此外，高SPF组的进展时间更长。比较DNA倍体与治疗反应时，无显著差异。
相似文献
1
Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?原发性肿瘤中的DNA倍体和S期分数能否预测转移性乳腺癌对化疗的反应？
Br J Cancer. 1995 May;71(5):1029-32. doi: 10.1038/bjc.1995.198.
2
Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.拓扑异构酶IIα及其他预后因素对晚期乳腺癌表柔比星化疗的预测价值
Br J Cancer. 1998 Jun;77(12):2267-73. doi: 10.1038/bjc.1998.377.
3
Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer.DNA倍体和S期分数在乳腺癌中的预后意义缺乏
Br J Cancer. 1992 Nov;66(5):925-9. doi: 10.1038/bjc.1992.387.
4
Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.多西他赛序贯氟尿嘧啶/表柔比星/环磷酰胺新辅助化疗治疗原发性乳腺癌患者。
Jpn J Clin Oncol. 2011 Jul;41(7):867-75. doi: 10.1093/jjco/hyr081.
5
Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy.前列腺腺癌的进展与生存：临床分期、Gleason分级、S期分数和DNA倍体的比较
Br J Cancer. 1994 Aug;70(2):309-14. doi: 10.1038/bjc.1994.298.
6
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.转移性乳腺癌患者中，与标准环磷酰胺、表柔比星和氟尿嘧啶（CEF）方案相比，加速强化CEF方案的疗效：意大利西北肿瘤学组-乳腺疾病组间多中心随机III期研究结果
J Clin Oncol. 2001 Apr 15;19(8):2213-21. doi: 10.1200/JCO.2001.19.8.2213.
7
High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study.大剂量表柔比星+环磷酰胺（HD-EC）用于转移性乳腺癌：一项剂量探索研究。
Onkologie. 1988 Dec;11(6):287-8. doi: 10.1159/000216559.
8
Markers of prognosis in breast cancer--the relationship between binding of the lectin HPA and histological grade, SPF, and ploidy.乳腺癌预后标志物——凝集素HPA的结合与组织学分级、增殖细胞核抗原标记指数及倍体之间的关系。
Breast Cancer Res Treat. 1993;25(3):247-56. doi: 10.1007/BF00689839.
9
Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.使用 70 基因分类器预测乳腺癌序贯紫杉醇和 5-氟尿嘧啶/表柔比星/环磷酰胺治疗的病理完全缓解。
Cancer. 2011 Aug 15;117(16):3682-90. doi: 10.1002/cncr.25953. Epub 2011 Feb 8.
10
Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.c-myc 扩增与乳腺癌新辅助化疗病理完全缓解的相关性。
Eur J Cancer. 2011 Aug;47(12):1779-88. doi: 10.1016/j.ejca.2011.06.017. Epub 2011 Jul 7.
引用本文的文献
1
DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy.卵巢癌腹膜转移癌的DNA倍体和S期分数分析：与临床病理因素及化疗反应的相关性
Onco Targets Ther. 2017 Sep 20;10:4657-4664. doi: 10.2147/OTT.S141117. eCollection 2017.
2
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.Ki67、组织学分级和雌激素受体状态的组合在1854例未经化疗的N0/N1期原发性乳腺癌女性中识别出一个低风险组。
Springerplus. 2013 Dec;2(1):111. doi: 10.1186/2193-1801-2-111. Epub 2013 Mar 14.
3
Identification of hypermethylated genes associated with cisplatin resistance in human cancers.鉴定与人类癌症顺铂耐药相关的高甲基化基因。
Cancer Res. 2010 Apr 1;70(7):2870-9. doi: 10.1158/0008-5472.CAN-09-3427. Epub 2010 Mar 9.
4
Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides.与传统组织学切片相比，组织芯片上细胞周期蛋白A评估在乳腺癌中的可靠性。
Br J Cancer. 2006 Jun 5;94(11):1697-702. doi: 10.1038/sj.bjc.6603147.
5
A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs.一种用于评估多细胞对化疗药物耐药性的静态肿瘤微区域模型。
Br J Cancer. 2005 Aug 8;93(3):302-9. doi: 10.1038/sj.bjc.6602710.
6
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.通过细胞周期蛋白A测量的高增殖率预示着软组织肉瘤患者对化疗有良好反应。
Br J Cancer. 1999 Nov;81(6):1017-21. doi: 10.1038/sj.bjc.6690801.
7
Increased doxorubicin uptake and toxicity in multicellular tumour spheroids treated with DC electrical fields.在接受直流电电场治疗的多细胞肿瘤球体中，阿霉素摄取和毒性增加。
Br J Cancer. 1999 Jun;80(8):1204-13. doi: 10.1038/sj.bjc.6690487.
8
Prognosis and prediction of response in breast cancer: the current role of the main biological markers.乳腺癌的预后及反应预测：主要生物标志物的当前作用
Cell Prolif. 1998 Jun-Aug;31(3-4):113-26. doi: 10.1046/j.1365-2184.1998.t01-1-00114.x.
9
A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer.晚期乳腺癌中预测细胞毒性治疗反应的肿瘤生物学因素的多变量分析。
Br J Cancer. 1998 Sep;78(6):812-5. doi: 10.1038/bjc.1998.584.
10
Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.拓扑异构酶IIα及其他预后因素对晚期乳腺癌表柔比星化疗的预测价值
Br J Cancer. 1998 Jun;77(12):2267-73. doi: 10.1038/bjc.1998.377.
本文引用的文献
1
Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.
J Clin Oncol. 1993 Mar;11(3):467-73. doi: 10.1200/JCO.1993.11.3.467.
2
How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer.如何整合原发性乳腺癌中类固醇激素受体、流式细胞术及其他预后信息。
Cancer. 1993 Mar 15;71(6 Suppl):2157-62. doi: 10.1002/1097-0142(19930315)71:6+<2157::aid-cncr2820711606>3.0.co;2-o.
3
Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates.
Eur J Cancer. 1993;29A(13):1843-8. doi: 10.1016/0959-8049(93)90534-m.
4
Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells.二十种抗肿瘤药物对增殖和非增殖人肿瘤细胞的杀伤效果差异
Cancer Res. 1981 Jun;41(6):2328-33.
5
Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.使用流式细胞术分析石蜡包埋病理材料细胞DNA含量的方法。
J Histochem Cytochem. 1983 Nov;31(11):1333-5. doi: 10.1177/31.11.6619538.
6
Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer.
Cancer Res. 1987 Sep 1;47(17):4729-35.
7
Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer.非整倍体DNA含量和肿瘤细胞的高S期分数与原发性乳腺癌患者的不良预后相关。
Eur J Cancer Clin Oncol. 1987 Mar;23(3):277-82. doi: 10.1016/0277-5379(87)90071-x.
8
Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer.乳腺癌的组织学分级、弹性组织变性、DNA倍体及对化疗的反应
Br J Cancer. 1987 Apr;55(4):455-7. doi: 10.1038/bjc.1987.89.
9
Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer.通过结合DNA指数和S期分数提高DNA流式细胞术在乳腺癌中的预后价值。一种提议的乳腺癌DNA直方图分类。
Cancer. 1988 Nov 15;62(10):2183-90. doi: 10.1002/1097-0142(19881115)62:10<2183::aid-cncr2820621019>3.0.co;2-b.
10
Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy.
J Natl Cancer Inst. 1989 Sep 20;81(18):1383-7. doi: 10.1093/jnci/81.18.1383.
Zotero 插件